Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Sanford-Burnham agree new diabetes collaboration

Pfizer and Sanford-Burnham agree new diabetes collaboration

16th August 2013

Pfizer is to collaborate with the Sanford-Burnham Medical Research Institute to identify therapeutic targets for preventing and treating complications of obesity and diabetes.

Scientists from both organisations will use novel screening tools – including systems-biology approaches and technologies developed by Sanford-Burnham – to determine new strategies for reducing insulin resistance among sufferers of these conditions.

The collaboration will leverage Sanford-Burnham's proven expertise in fundamental disease biology and muscle metabolism and Pfizer's drug discovery capabilities, with the overall goal of tackling an increasingly urgent public health burden.

Tim Rolph, vice-president and head of the cardiovascular and metabolic diseases research unit at Pfizer, said: "Pfizer's collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes."

It comes after the company agreed new research collaborations with the Newcastle upon Tyne Hospitals NHS Foundation Trust and Children's Hospital of Philadelphia.ADNFCR-8000103-ID-801625885-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.